Journal: BMC Cancer

Article Title: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

doi: 10.1186/s12885-015-1730-y

Figure Lengend Snippet: Cost, LYs and QALYs per person for each screening strategy, and the incremental cost, LYs and QALYs of a screening strategy compared with no screening

Article Snippet: The strategies were listed below: i. no screening ii. annual G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) v. biennial I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) ix. ix. colonoscopy every 10 years With the one-sample per screening round, people who had positive G-FOBT or qualitative I-FOBT result were assumed to proceed immediately to a colonoscopy to confirm the result.

Techniques:

Journal: BMC Cancer

Article Title: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

doi: 10.1186/s12885-015-1730-y

Figure Lengend Snippet: Optimal strategy according to the Ceiling Ratio in Base-case and Multivariate Scenarios

Article Snippet: The strategies were listed below: i. no screening ii. annual G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) v. biennial I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) ix. ix. colonoscopy every 10 years With the one-sample per screening round, people who had positive G-FOBT or qualitative I-FOBT result were assumed to proceed immediately to a colonoscopy to confirm the result.

Techniques:

Journal: BMC Cancer

Article Title: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

doi: 10.1186/s12885-015-1730-y

Figure Lengend Snippet: The ICER in terms of $/LYs or $/QALYs of a Screening Strategy from the Other Competing Strategies

Article Snippet: The strategies were listed below: i. no screening ii. annual G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) v. biennial I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) ix. ix. colonoscopy every 10 years With the one-sample per screening round, people who had positive G-FOBT or qualitative I-FOBT result were assumed to proceed immediately to a colonoscopy to confirm the result.

Techniques:

Journal: BMC Cancer

Article Title: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

doi: 10.1186/s12885-015-1730-y

Figure Lengend Snippet: Cost, LYs and QALYs per person for each screening strategy, and the incremental cost, LYs and QALYs of a screening strategy compared with no screening

Article Snippet: The strategies were listed below: i. no screening ii. annual G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) v. biennial I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) ix. ix. colonoscopy every 10 years With the one-sample per screening round, people who had positive G-FOBT or qualitative I-FOBT result were assumed to proceed immediately to a colonoscopy to confirm the result.

Techniques:

Journal: BMC Cancer

Article Title: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

doi: 10.1186/s12885-015-1730-y

Figure Lengend Snippet: Optimal strategy according to the Ceiling Ratio in Base-case and Multivariate Scenarios

Article Snippet: The strategies were listed below: i. no screening ii. annual G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) v. biennial I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) ix. ix. colonoscopy every 10 years With the one-sample per screening round, people who had positive G-FOBT or qualitative I-FOBT result were assumed to proceed immediately to a colonoscopy to confirm the result.

Techniques:

Journal: BMC Cancer

Article Title: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

doi: 10.1186/s12885-015-1730-y

Figure Lengend Snippet: The ICER in terms of $/LYs or $/QALYs of a Screening Strategy from the Other Competing Strategies

Article Snippet: The strategies were listed below: i. no screening ii. annual G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman Coulter, Inc., California, USA) v. biennial I-FOBT (actim Fecal Blood, Medix Biochemica, Finland) ix. ix. colonoscopy every 10 years With the one-sample per screening round, people who had positive G-FOBT or qualitative I-FOBT result were assumed to proceed immediately to a colonoscopy to confirm the result.

Techniques: